NCT03925402 is a clinical trial of Ertapenem in Bacteremia, sponsored by Phramongkutklao College of Medicine and Hospital.

Who is sponsoring NCT03925402?

NCT03925402 is sponsored by Phramongkutklao College of Medicine and Hospital.

What drugs are being tested in NCT03925402?

Interventions in NCT03925402: Ertapenem, Carbapenems.

What condition does NCT03925402 study?

NCT03925402 studies Bacteremia, Infection, Bacterial.

Is NCT03925402 still recruiting?

NCT03925402 is currently completed. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT03925402

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ertapenem for Initial Empirical Treatment of Third Generation Cephalosporin Resistant Enterobacteriaceae Bacteremia

Completed Last updated 29 March 2023

What this trial tests

trial testing Ertapenem in Bacteremia in 427 participants. Completed in 1 October 2022.

Timeline

15 May 2019

Primary endpoint
31 December 2021

1 October 2022

Quick facts

Lead sponsor	Phramongkutklao College of Medicine and Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	427
Start date	15 May 2019
Primary completion	31 December 2021
Estimated completion	1 October 2022
Sites	1 location across Thailand

Drugs / interventions tested

Ertapenem (ERTAPENEM) — full drug profile →
Carbapenems — full drug profile →

Conditions studied

Bacteremia — all drugs for Bacteremia →
Infection, Bacterial — all drugs for Infection, Bacterial →

Sponsor

Phramongkutklao College of Medicine and Hospital

Who can join

Adults 18 to 99, any sex, with Bacteremia or Infection, Bacterial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to assess whether ertapenem as an empiric treatment of third-generation-cephalosporin resistant Enterobacteriaceae (3GCRE) bacteremia is non-inferior to other carbapenems in term of 30-day mortality.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Towards optimizing carbapenem selection in stewardship strategies: a prospective propensity score-matched study of ertapenem versus class 2 carbapenems for empirical treatment of third-generation cephalosporin-resistant Enterobacterales bacteraemia.
Vasikasin V, Panuvatvanich B, Rawson TM, Holmes AH, et al · · 2023 · cited 1× · PMID 37252945 · DOI 10.1093/jac/dkad165

Verify or expand the search:

Other trials of Ertapenem

Trials testing the same drug.

NCT06920147 — PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network · Phase 4 · not yet recruiting
NCT05645757 — Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777) · Phase 1 · completed
NCT04502095 — Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy · Phase 4 · completed
NCT03788967 — Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) · Phase 3 · completed
NCT04505683 — A Study to Assess Efficacy and Safety Intravenous Benapenem in Patients With Complicated Urinary Tract Infection (cUTI) · Phase 2, PHASE3 · completed

Other recruiting trials for Bacteremia

Currently open trials in the same condition.

NCT07134751 — Febrile Infants Swedish Study · recruiting
NCT07126106 — Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU Patients · recruiting
NCT06821282 — Surveillance of AMR in DRC · recruiting
NCT06425367 — Impact of Performing a Rapid Antibiotic Susceptibility Test on Antibiotic Therapy Adaptation in Adult Patients with Ente · NA · recruiting
NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting

Other Phramongkutklao College of Medicine and Hospital trials

Trials by the same sponsor.

NCT07366450 — High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma · NA · not yet recruiting
NCT07014371 — Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA) · NA · recruiting
NCT06491342 — Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease · NA · completed
NCT06279507 — Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis · Phase 4 · unknown
NCT06049771 — The Population Pharmacokinetics Study of Tigecycline and Pharmacokinetics- Pharmacodynamics Index in Patients With Carba · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03925402 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Phramongkutklao College of Medicine and Hospital
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03925402.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing